The five-year results of a prospective randomised trial of radical mastectomy (179 patients) versus radical mastectomy followed by adjuvant chemotherapy (207 patients) were analysed. Chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF). Both relapse-free survival (controls 44M6%, CMF group 59-5%) and total survival (controls 66-2%, CMF group 78-4%) were significantly improved. The findings were related to the number of diseased axillary nodes and amount of drug administered, and were independent of CMF-induced amenorrhoea. Menopausal state alone appeared to affect the five-year results only when the amount of drug administered was not taken into account. Salvage treatment at first relapse failed to improve total survival in the controls compared with the CMF group. Acute toxic manifestations were moderate and reversible. Chronic organ damage and increased incidence of second neoplasms (controls 17%, CMF group 14%) were not observed.
Introduction
In June 1973 we began a prospective randomised study of women with operable breast cancer utilising combined chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF). Our aim was to find whether prolonged administration of CMF after operation would alter the rates of relapse-free survival and total survival in patients with metastatic deposits in axillary lymph nodes, who are at high risk of early recurrence after surgery. ' At the time the standard primary treatment for resectable breast carcinoma was radical surgery with or without postoperative irradiation, which were yielding a plateau of therapeutic results.2 Combined-modality treatment was known to be effective in experimental animals,' while in clinical cancer this approach had been successful only in some paediatric neoplasms. In breast cancer, however, initial attempts with adjuvant single-agent chemotherapy had given inconsistent results,4 and none of the published reports was conclusive.
Preliminary findings of the adjuvant CMF programme5-7 and of similar studies8 9 suggested that the new strategy was correct and worthy of more-widespread attention. The true efficacy of any treatment for operable breast cancer is best represented by the results at 10 years. We, however, present our results at five years in an attempt to show that the multimodality approach with cyclical combination chemotherapy is a new, important advance in the primary management of mammary carcinoma.
Subjects and methods
The trial was initiated on 1 June 1973, and patients were collected consecutively up to 11 September 1975. All of the women received their surgical and medical treatment and regular follow-up examinations at this institute. The criteria for inclusion in the trial have been detailed elsewhere. 5 6Briefly, eligible patients had potentially curable breast cancer (TNM classification Tl-T2,T3-; No-N1a-Nib, Mo), histologically proved metastases in axillary lymph nodes, and no evidence of disease in distant sites. They lived close enough to the institute to receive chemotherapy and attend for regular follow-up. Adequate bone marrow reserve as well as normally functioning liver and kidneys were also required. Women over 75 or suffering from other malignancies (except curable skin cancer) or Table II shows that there was a definite dose-response effect, and at each dosage the five-year relapse-free survival was similar in the two menopausal groups. Furthermore, in women who received low-dose CMF (less than 65% of the planned dose) the relapse-free survival was similar to that of controls. Table III shows the relapse-free survival and total survival related to age. Although the subgroups were small, and with the possible exception of patients over 65, at each decade of age therapeutic results were apparently better with CMF. Nevertheless, the extent of nodal disease was not always evenly distributed in each age group, so that low-dose chemotherapy as well as the prevalence of three or more affected nodes in the CMF group may have been more important than age over 65.
SITE OF FIRST RELAPSE
No substantial difference in the pattem of treatment failure was evident between the control and CMF-treated groups. Local and 100. 
Discussion
This study of women with operable breast cancer showed significantly improved overall results at five years in the group given CMF after operation. Hence several biological and practical factors must be considered. The first is the observation that CMF chemotherapy, which produces an objective response (usually partial) in 50-55% of women with overt metastatic breast cancer,9 14 can exert a therapeutic effect on micrometastases that may last for at least five years. Thus laboratory findings3 that neoplastic cells may be more vulnerable to the same cytotoxic drugs in more favourable kinetic conditionsthat is, minimal residual disease-are confirmed clinically in an important solid tumour such as primary breast cancer with metastases in axillary lymph nodes. The variations in outcome with different degrees of axillary nodal disease probably further support the laboratory findings.
A second consideration concerns another important correlation between laboratory and clinical data. As in a separate, larger series of CMF-treated patients,12 we observed a dose-response effect of adjuvant chemotherapy. Regardless of menopausal state, clinical benefit increased with the amount of drug administered and was significant for patients receiving nearly the full dose. In contrast, patients given low-dose chemotherapy showed relapse-free survival rates similar to those ofthe controls. We recently confirmed the important role of drug dosage in a two-year, prospective randomised trial of two dose schedules of adjuvant chemotherapy in postmenopausal women. Relapse-free survival was significantly inferior in the group beginning with low-dose (< 65%) CMFP (cyclophosphamide, methotrexate, fluorouracil, prednisone) compared with that of patients given the full dose regimen from the first treatment cycle.15 All these findings confirm that the outcome of combined treatment depend on the adequacy of both treatment modalities (local and regional, and systemic).
A third consideration concerns untoward effects of adjuvant chemotherapy. Our findings suggest that the incidence and degree of early as well as late toxicity are acceptable. Aside from frequent vomiting after each injection of methotrexate and fluorouracil, gastric disturbance while receiving oral cyclophosphamide was probably the most consistent side effect. Frank alopecia and haemorrhagic cystitis were rare.5 6 While myelosuppression and chemical cystitis were dose-limiting factors in all age groups, all toxic manifestations but amenorrhoea in late premenopausal women were reversible. In our series late toxicity such as chronic organ damage and increased incidence of second neoplasms was not observed. Longer follow-up will, however, be needed to assess the true incidence of late morbidity. Some psychological and socioeconomic problems resulting from prolonged adjuvant chemotherapy were recognised during the study but were not quantitatively defined. Overall our results in terms of relapse-free survival and total survival appeared to outweigh the disadvantages of early toxicity and psychological and financial difficulties.
In conclusion the five-year results of our first adjuvant CMF programme have shown the efficacy of a multimodal approach in a high-risk group with resectable mammary carcinoma. More work is required, however, and other studies'-21 have examined the value of adjuvant chemotherapy in relation to critical variables such as menopausal state. Clinical investigation continues to be indicated, and studies are in progress testing hormonal manipulation alone or with chemotherapy, the role of immune stimulation, the effect of chemotherapy in high-risk groups of women with tumours not affecting axillary lymph nodes, and non-cross-resistant regimens. As a result of multicentre studies future analyses, by critically reconsidering prognostic variables, will better define the subgroups who can most benefit from adjuvant therapy and provide more-detailed information on type and duration of treatment for given variables.
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Requests for reprints should be addressed to: Dr Gianni Bonadonna, Istituto Nazionale Tumori, Via Venezian, 1 Cimetidine is available as tablets, a syrup, or a preparation for intravenous injection, but in some patients administration by the intramuscular route is desirable. We therefore studied the safety and acceptability of intramuscular injection of cimetidine.
Patients, methods, and results
We studied 27 men and 11 women aged 22-79 (median 65.5) years.
Twenty-five had duodenal or gastric ulceration, five oesophagitis, two duodenitis, two dyspepsia, and one each gastric erosions, bleeding oesophageal varices, a deformed duodenal bulb, and pruritus. All were inpatients already receiving oral cimetidine 200 mg thrice daily plus 400 mg at night.
Nineteen patients were studied in a double-blind cross-over trial. On the first day the midday dose of cimetidine was replaced by either intramuscular cimetidine 200 mg and a placebo tablet, or a placebo injection and cimetidine 200 mg by mouth. The next day the alternative treatment was given, the order being randomised. The two injections were given into opposite buttocks. Blood samples for creatine kinase activity were taken immediately before, and 24 hours after, each injection. Pain at the injection site was assessed as none, mild, moderate, or severe 10 minutes and six hours after each injection, and at the same time the site was inspected for any local reaction. The remaining 19 patients received intramuscular cimetidine 200 mg six hourly for 24 hours, oral cimetidine being omitted. Each injection site was numbered serially, and two to four hours after the last injection the appearance of each site was noted.
The cimetidine injection (200 mg in 2 ml) for intramuscular use was the same formulation as the standard intravenous preparation. The placebo injection was 2 ml 0-9 % sodium chloride. All injections were given by trained nursing staff. Written informed consent was obtained from each patient, and the study had the approval of the hospital ethical committee.
After a single intramuscular injection of cimetidine one patient reported mild pain at 10 minutes that had resolved by six hours and another had moderate pain at six hours that had disappeared by the next day. After placebo injection two other patients reported mild pain at six hours but none had pain at 10 minutes. The injection sites appeared normal except after a placebo injection in one patient, who had erythema at 10 minutes that had resolved by six hours. Serum creatine kinase activity remained normal after all injections. One patient felt light-headed transiently after injection of cimetidine, while another complained of aching in the buttock for a few hours after both injections.
Of the 19 patients receiving intramuscular cimetidine six hourly, 14 had no reaction at any of the injection sites. One patient had erythema with some swelling at one site and erythema alone at another site. The remaining four patients had erythema at one injection site. No adverse events occurred and no patient had to be withdrawn from either part of the study.
Comment
Our study showed that reactions at the injection site were uncommon and as likely with placebo as with intramuscular cimetidine. Though 
Family study
The brachydactyly consisted of hypoplasia of the second, third, and fifth middle phalanges of both hands (figure), the severity of the condition varying among family members. In some cases the hypoplasia was restricted to the fifth finger, whereas in others the fourth and fifth metacarpals were also affected. One subject had changes in the segmental ratios of phalanges and metatarsals in both feet.
Brachydactyly had been present in five out of seven siblings. Three of the five had died of colorectal cancer, and the other two had died of unrelated disorders at 29 and 68 years of age. One of the two siblings without hand
